CN Patent

CN102643275B — 一种达莎替尼n-6晶型新的制备方法

Assigned to Jiangsu Simcere Pharmaceutical Co Ltd · Expires 2016-04-20 · 10y expired

What this patent protects

本发明提供了一种Dasatinib？N-6晶型的制备方法，即将Dasatinib溶解在甲醇中，然后冷却结晶，得到上述Dasatinib？N-6晶型。

USPTO Abstract

本发明提供了一种Dasatinib？N-6晶型的制备方法，即将Dasatinib溶解在甲醇中，然后冷却结晶，得到上述Dasatinib？N-6晶型。

Drugs covered by this patent

Patent Metadata

Patent number
CN102643275B
Jurisdiction
CN
Classification
—
Expires
2016-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.